The biotech sector has recently seen a pullback driven largely by Intellia Therapeutics' (NTLA) stock drop following trial setbacks. This decline has created a compelling buying opportunity for Vertex Pharmaceuticals ). Vertex boasts a strong, diversified portfolio with approved blockbuster drugs and promising pipeline candidates. Analysts expe
ct steady growth and see about 20% upside over the next 1-2 years. Thanks to the sector-wide weakness caused by NTLA, Vertex is now attractively valued and presents a more stable